Trial Profile
A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo) in Subjects With Recurrent or Progressive Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alaunos Therapeutics; ZIOPHARM Oncology
- 03 Nov 2021 Status changed from active, no longer recruiting to completed.
- 19 Nov 2020 According to a ZIOPHARM Oncology media release, preliminary data from this study were presented Dr. Lukas at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting.
- 19 Nov 2020 Preliminary data from this study presented in a ZIOPHARM Oncology media release.